Tizetatug rezetecan (SHR-A1921) is an Antibody-drug Conjugate (ADC) composed of antibody Tizetatug and MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan. Tizetatug rezetecan can be used for the research of cancer.

TIPARP-IN-1 (Compound 15) is a selective PARP7 (TIPARP) (2,3,7,8-Tetrachlorodiben-zo-p-dioxin(TCDD)-inducible PARP) inhibitor with an IC50 of 2.15 nM. TIPARP-IN-1 can restore IFN signaling pathway in tumors by inhibiting TIPARP. TIPARP-IN-1 selectively activates the anti-tumor immune response in the tumor microenvironment and avoids the production of systemic cytokines. TIPARP-IN-1 can be used for research of head and neck squamous cell carcinoma.

Tilnoprofen arbamel is a biochemical reagent.

Ticagrelor acetonide (Isopropylidene ticagrelor) (Compound 7) is a drug intermediate that can be used for the synthesis of lysine-specific demethylase (LSD1) inhibitors.

Tiadenol is an absorbable hypolipidemic agent. Tiadenol can effectively reduce triglycerides and decrease the level of apolipoprotein E in very low-density lipoproteins in hyperlipoproteinemia. Tiadenol causes hepatomegaly in rats and affects their hepatic lipid levels, cholesterol synthesis and absorption at high doses. Tiadenol can be used in the research of endocrine and metabolic diseases such as hyperlipidemia.

THR-β modulator-3 (Compound 75-2) is a THR-β modulator. THR-β modulator-3reduces total fat mass, body weight. THR-β modulator-3 improves obesity.

Thalidomide-azetidine-COOH is an E3 ligase ligand-linker conjugate containing a CRBN-based ligand and linker, which can be used to synthesize PROTAC.

Thalidomide-5-NH-C9-acid is a synthetic E3 ligase ligand-linker conjugate containing a Thalidomide-based Cereblon ligand and one linker.

Thalidomide-5-F-6-piperidinylpiperazin is an ligands for E3 ligase-linker conjugate, which is used for the synthesis of PROTAC CDK9 degrader-9.

TGR5 agonist 10 is a selective, allosteric and orally active Takeda G protein coupled receptor 5 (TGR5) agonist with EC50s of 0.8 μM and 0.6 μM for human TGR5 and mouse TGR5, respectively. TGR5 agonist 10 demonstrates selectivity for TGR5 over FXR. TGR5 agonist 10 activates hTGR5 and mTGR5 to induce cAMP accumulation, and positively modulates lithocholic acid functional activity and potency at hTGR5, with higher selectivity for cAMP formation over β-arrestin2 recruitment. TGR5 agonist 10 exerts glucose-lowering effects in Mus musculus oral glucose tolerance tests. TGR5 agonist 10 can be used for the research of diabetes.

TGF-β/Smad-IN-3 (Compound 4w) is an effective TGF-β/Smad inhibitor. TGF-β/Smad-IN-3 exerts anti-pulmonary fibrosis activity by simultaneously inhibiting the TGF-β/Smad and MAPK signaling pathways. TGF-β/Smad-IN-3 significantly inhibits collagen deposition induced by TGF-β1, with its IC50 value being 3.21 μM. TGF-β/Smad-IN-3 has an IC₅₀ of 46.77 nM for the autocrine motility factor (ATX). TGF-β/Smad-IN-3 significantly reduces the expression levels of α-SMA, COL1A1 and FN in TGF-β1-induced CCC-HPF-1 cells, and effectively inhibited TGF-β1-induced cell migration. TGF-β/Smad-IN-3 can be used for the study of pulmonary fibrosis.

tert-Butyl 4-(methylamino)butylcarbamate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 4-(3-hydroxypropyl)tetrahydropyridine-1(2H)-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 4-(2-aminoethyl)piperazine-1-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 3-cyanoazetidine-1-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-Butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate hydrochloride is a PROTAC linker that can be used in the synthesis of PROTACs.

tert-butyl (5-bromopentyl)carbamate is a PROTAC linker that can be used in the synthesis of PROTACs.

Terfenadine N-oxide, an N-oxide derivative of Terfenadine, is a histamine H1 receptor antagonist (IC50 = 2.73 μM) and an hERG potassium channel inhibitor (IC50 = 0.698 μM). Terfenadine N-oxide is can be used for the research of histamine-related allergic diseases and hERG channel-associated arrhythmias.

Terbequinil (SR-25776) is a potent orally active Gamma-aminobutyric acid A (GABAA) receptor inverse agonist. Terbequinil can be used for research on nervous system diseases.

Terazosin-md (compound TZ-md), a derivative of both Alfuzosin and Terazosin, is an orally active α1-adrenergic receptor antagonist. Terazosin-md has the functions of improving mitochondrial metabolism, degrading various pathological protein accumulations and improving the function of vascular endothelial cells. Terazosin-md shows effect in a mouse model with Alzheimer's disease. Terazosin-md can be used for research in Alzheimer's disease and related complications, and diseases associated with protein accumulation and metabolic disorders.

Tenivastatin calcium is a HMG-CoA reductase inhibitor. Tenivastatin calcium can reduce blood lipid level can be used for the research of hyperlipidemia.

Telomeric G4s ligand 2 is an orally active, selective ligand of telomeric G-quadruplex (G4), with an IC50 of 0.4 μM. Telomeric G4s ligand 2 binds to dimeric telomeric G4, inhibits the activities of DHX36 and BLM helicases. Telomeric G4s ligand 2 activates cGAS-STING and TERRA-ZBP1 pathways, inducing autophagy and G2/M cell cycle arrest, and exhibits antiproliferative effects across cancer cell lines. Telomeric G4s ligand 2 can be used for the study of colorectal cancer.

TEI-6122 is a 7-thiaprostaglandin E1 derivative. TEI-6122 can reduce urinary protein and suppressthe increase of blood urea nitrogen. TEI-6122 can inhibit monocyte chemoattractant protein-1 induced chemotaxis. TEI-6122 can be used for the research of inflammation, such as nephritis.

Teglicar chloride (ST1326 chloride) is an orally active, reversible, mixed-type, selective inhibitor of hepatic carnitine palmitoyltransferase I (L-CPT I), with an IC50 of 1.1 μM against rat L-CPT I. Teglicar chloride reduces serum glucose levels. Teglicar chloride exhibits antiketotic activity in normal fasted rats. Teglicar chloride can be used in research related to type 2 diabetes and ketoacidosis.

Tedisamil (KC-8857) dihydrochloride is an antiarrhythmic compound with important biological activities. Tedisamil dihydrochloride exhibits a significant slowing effect on heart rate, which is achieved by inhibiting the transient outward potassium current (I(to)) in the atrium. Tedisamil dihydrochloride inhibits multiple potassium currents, including IK, K(ATP), and PKA-activated chloride channels, thereby prolonging the cardiac action potential and QT interval, and increasing cardiac reentry. Tedisamil dihydrochloride has antiarrhythmic effects on ventricular arrhythmias and atrial flutter in animal models.

TDG-IN-1 is an orally active, selective small-molecule inhibitor of thymine DNA glycosylase (TDG) with a Ka of 1.46 nM. TDG-IN-1 impairs the DNA-binding ability of TDG, induces downregulated expression of DHX9, accumulation of double-stranded RNA, and activation of the RIG-I/MDA5-MAVS pathway, while acting as a tumor suppressor, innate immune activator and immunostimulant. TDG-IN-1 inhibits the growth of p53-deficient tumor cells and xenograft tumors, and exerts a synthetic lethal effect with p53. TDG-IN-1 is applicable to the research of p53-deficient cancers.

TCO-amine hydrochloride is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. TCO-amine hydrochloride is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.

TCCNeu5Ac (compound H-56) is a high-affinity and selective trisaccharide glycan ligand for Siglec-1 (CD169). TCCNeu5Ac azide can be conjugated to lipids to selectively target cells expressing either murine or human CD169 in vitro, exhibiting in vivo targeting to CD169-positive macrophages. TCCNeu5Ac can be used for in vivo macrophage delivery.

TBC-4746 is a α4β1/α4β7 integrin antagonist. TBC-4746 can be used in the research of asthma and multiple sclerosis.

Talsupram is a selective noradrenaline inhibitor that has a high affinity for the noradrenaline transporter. Talsupram exhibits anti-hyperalgesic effects. Talsupram can decrease ethanol intake to the levels prior to REM-induced deprivation in rat model.